Fifteen million people on antiretroviral treatment by 2015: Treatment as prevention

Current Opinion in HIV and AIDS

Volumn 8, Issue 1, 2013, Pages 41-49

  Granich, Reuben ^a   Williams, Brian ^b   Montaner, Julio ^c  

^a UNAIDS   (Switzerland)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c British Columbia Center for Excellence in HIV/AIDS   (Canada)

Author keywords

HIV; treatment as prevention; tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT;

DISEASE TRANSMISSION; EARLY DIAGNOSIS; EVALUATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; MEDICAL LITERATURE; MONITORING; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANTI-HIV AGENTS; HEALTH POLICY; HIV INFECTIONS; HUMANS; TUBERCULOSIS; WORLD HEALTH;

EID: 84871923564     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835b80dd     Document Type: Review

References (86)

1. Clinton HR. Remarks on 'Creating an AIDS-Free Generation'. National Institutes of Health, Masur Auditorium, Bethesda, Maryland, USA; 2011. http://www.state.gov/secretary/rm/2011/11/176810.htm. [Accessed 5 November 2012] Important speech affirming United States' commitment to international HIV response.
2. Barre-Sinoussi F CJ, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (New York, NY 1983; 220:868-871. (Pubitemid 13080157)
3. UNAIDS. AIDS at 30: Nations at the Cross Roads. Geneva, Switzerland 2011 http://www.unaids.org/unaids-resources/aidsat30/aids-at-30.pdf. [Accessed 5 November 2012] Status report from UNAIDS after 30 years of epidemic.
4. UNAIDS. Together we will end AIDS http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2012/20120718-together wewillendaids-en.pdf 2012. Report from UNAIDS with details regarding the status of treatment expansion.
5. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. 2010: http://whqlibdoc.who.int/publications/2010/ 9789241500395-eng.pdf.
6. UNAIDS. Global AIDS response continues to show results as a record number if people access treatment and rates of new HIV infections fall by nearly 25%. Press release. June 3, 2011. Press release including treatment access results.
7. WHO. Global tuberculosis control: a short update to the 2009 report. http://whqlibdoc.who.int/publications/2009/9789241598866-eng.pdf.WHOand Stop TB Partnership: 2009 update tuberculosis facts. http://www.stoptb.org/assets/ documents/resources/factsheets/tbfactsheet-2009update-one-page.pdf.
8. WHO. Global Tuberculosis Report 2011. http://www.who.int/tb/publications/ global-report/2011/gtbr11-full.pdf. http://apps.who.int/iris/bitstream/10665/ 75938/1/9789241564502-eng.pdf. [Accessed 5 November 2012] Summary of global TB control efforts as of end of 2010.
9. UNAIDS. Impact of the global financial and economic crisis on the AIDS response. 25th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland 8-10 December 2009.
10. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4\+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954. (Pubitemid 27255797)
11. USAID Administrator Natsios Press Remarks on HIV/AIDS in Africa Andrew Natsios, USAID Administrator Press Remarks En Route to South Africa With Secretary Powell Washington, DC May 24, 2001 http://2001-2009.state. gov/g/oes/rls/rm/3833.htm. [Accessed 5 November 2012]
12. Schwartlander B, Grubb I, Perrië ns J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 2006; 368:541-546. (Pubitemid 44177530)
13. Nolen S. 28 stories of AIDS in Africa, Portobello Books: 108. 2007.
14. PEPFAR. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Seventh Annual Report to Congress. 2011 Washington D.C. http://www.pepfar.gov/ press/seventhannualreport/. [Accessed 5 November 2012] PEPFAR report to Congress with 2010 achievements.
15. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva 2011 http://whqlibdoc.who.int/publications/2011/ 9789241502986-eng.pdf. [Accessed 5 November 2012] WHO report on progress towards universal access as of end of 2010.
16. New study finds cost of treating HIV patients is far lower than commonly believed; agreement with generic drug makers will bring prices down even further 2012 Clinton Health Access Initiative, Washington, D.C. (Press Release) http://www.clintonfoundation.org/main/news-and-media/pressreleases-and- statements/press-release-agreement-with-generic-drug-makerswill-bring-prices- down-even-further.html. [Accessed 5 November 2012] Report describing the cost of treatment delivery at facility level.
17. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
18. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536. (Pubitemid 44142776)
19. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
20. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012; 9:e1001270; http://www.plosmedicine.org/article/ info%3Adoi% 2F10.1371%2Fjournal.pmed.1001270. [Accessed 5 November 2012].
21. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203. doi:10.1371/journal.pmed.0050203.
22. CD4\+ count-guided interruption of antiretroviral treatment. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group N Engl J Med 2006; 355:2283-2296.
23. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
24. Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010; 24:F11-F14.
25. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012; 54:714-723.
26. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
27. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 5: e11068. doi:10.1371/journal.pone.0011068.
28. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539.
29. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338:b1649.
30. Tanser F, Bärnighausen T, Grapsa E, Newell M. Effect of ART coverage on rate of new HIV infections in a hyper-endemic, rural population: South Africa. Paper #136LB presented at Conference on Retroviruses and Opportunistic Infections, March 5-8th, 2012 Seattle, USA. http://www.retroconference. org/2012b/Abstracts/45379.htm. [Accessed 5 November 2012]
31. Achievements in public health. Reduction in perinatal transmission of HIV infection: United States, 1985-2005. MMWR 2006; 55:592-597.
32. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654. (Pubitemid 30070912)
33. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198:59-67. (Pubitemid 351920290)
34. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
35. HallettTB,BaetenJM,HeffronR, etal. Optimalusesofantiretroviralsforprevention in HIV-1 serodiscordant heterosexual couples inSouth Africa: a modelling study. PLoS Med 8: e1001123. doi:10.1371/journal.pmed.1001123. Study examining the optimal use of antiretrovirals in South Africa with an emphasis on the role of pre-exposure prophylaxis.
36. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-493. (Pubitemid 34826854)
37. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012; 9:e1001245. doi:10.1371/journal.pmed.1001245. Study comparingmodels examining the potential impact treatment on HIV incidence.
38. Smith RJ, Okano JT, Kahn JS, et al. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327:697-701.
39. Antiretroviral treatment as prevention (TASP) of HIV and TB: Programmatic update. WHO 2012 Geneva http://whqlibdoc.who.int/hq/2012/WHO-HIV-2012.12-eng. pdf. [Accessed 5 November 2012] WHO advice regarding the use of ART for prevention including definition of TasP for preventing HIV and TB morbidity, mortality and transmission irrespective of CD4 count levels.
40. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples. Recommendations for a public health approach WHO Geneva 2012 http://whqlibdoc. who.int/publications/2012/9789241501972-eng.pdf First WHO guidance regarding the use of ART to prevent HIV transmission.
41. Gupta S, Granich R, Suthar A, et al. Three Is for HIV/TB and early ART to prevent HIV and TB: policy review of HIV and TB guidelines for high HIV/TBburden African countries: 19th International AIDS Conference Washington D.C. 2012: Abstract no. WEPDD0205. Abstract regarding policy review of national ART and HIV/TB guidelines.
42. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
43. 2011 Political Declaration on HIV/AIDS New York 2011 http://www.unaids. org/en/media/unaids/contentassets/documents/document/2011/06/ 20110610-UN-A-RES-65-277-en.pdf United Nations declaration regarding commitment to confront HIV/AIDS.
44. Schwartlander B, Stover J, Hallett T, et al. Towards an improved investment approachforaneffectiveresponsetoHIV/AIDS.Lancet2011;377:2031-2041.
45. UNAIDS. HIV prevention revolution. 2010; http://www. hivpreventioncommission. com/index.php?q=node/43. [Accessed 5 November 2012]
46. Lodi S, Phillips A, Touloumi G, et al. Time from human immunodeficiency virus seroconversion to reaching CD4\+ cell count thresholds
47. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77. (Pubitemid 47514615)
48. Holmberg SD, Palella FJ Jr, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis 2004; 39:1699-1704. (Pubitemid 39578548)
49. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-690. (Pubitemid 44200639)
50. San Lio MM, Carbini R, Germano P, et al. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clin Infect Dis 2008; 46:1609-1616. (Pubitemid 351706745)
51. Bunnell RE, Nassozi J, Marum E, et al. Living with discordance: knowledge, challenges, and prevention strategies of HIV-discordant couples in Uganda. AIDS Care 2005; 17:999-1012. (Pubitemid 41499313)
52. Lifshay J, Nakayiwa S, King R, et al. Partners at risk: motivations, strategies, and challenges to HIV transmission risk reduction among HIV-infected men and women in Uganda. AIDS Care 2009; 21:715-724.
53. Bechange S, Bunnell R, Awor A, et al. Two-year follow-up of sexual behavior among HIV-uninfected household members of adults taking antiretroviral therapy in Uganda: no evidence of disinhibition. AIDS Behav 2010; 14:816-823.
54. Berhan A, Berhan Y. Is the sexual behaviour of HIV patients on antiretroviral therapy safe or risky in sub-Saharan Africa? Meta-analysis and meta-regression. AIDS Res Ther 2012; 9:14. Meta-analysis discussing the sexual behavior of people on treatment.
55. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92. (Pubitemid 41818118)
56. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292:224-236. (Pubitemid 38918000)
57. Venkatesh KK, de Bruyn G, Lurie MN, et al. Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS 2010; 24:2687-2696.
58. Marconi VC, Grandits GA, Weintrob AC, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther 2010; 7:14.
59. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-3884. (Pubitemid 351723493)
60. Barth RE, van der Loeff MF, Schuurman R, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-166.
61. Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192. (Pubitemid 46869811)
62. Mofenson LM. Prevention in neglected subpopulations: prevention of motherto-child transmission of HIV infection. Clin Infect Dis 2010; 50 (Suppl 3): S130-S148.
63. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368.
64. Chaix ML, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009; 23:717-724.
65. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50:98-105.
66. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr 2008; 49:266-271.
67. Uy J, Armon C, Buchacz K, et al. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009; 51:450-453.
68. Korenromp EL, Williams BG, Schmid GP, Dye C. Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection: a quantitative review. PLoS ONE 2009; 4:e5950. doi:10.1371/journal.pone. 0005950.
69. Williams BG, Korenromp EL, Gouws E, et al. HIV infection, antiretroviral therapy, and CD4\+ cell count distributions in African populations. J Infect Dis 2006; 194:1450-1458. (Pubitemid 44706515)
70. Phillips AN, Lampe FC, Smith CJ, et al. Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion. AIDS 2010; 24:1561-1567.
71. Schechter M, Tuboi SH. Discordant immunological and virological responses to antiretroviral therapy. J Antimicrob Chemother 2006; 58:506-510. (Pubitemid 44288113)
72. Harries AD, Zachariah R, Lawn SD, Rosen S. Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010; 15 (Suppl 1):70-75.
73. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15 (Suppl 1):1-15.
74. Bendavid E, Wood R, Katzenstein DA, et al. Expanding antiretroviral options in resource-limited settings-a cost-effectiveness analysis. J Acquir Immune Defic Syndr 2009; 52:106-113.
75. Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE 2012; 7:e30216. doi:10.1371/journal.pone.0030216.
76. Resch S, Korenromp E, Stover J, et al. Economic returns to investment in AIDS treatment in low and middle income countries. PLoS ONE 2011; 6:e25310. doi:10.1371/journal.pone.0025310.
77. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378:256-268.
78. Cohen T, Corbett EL. Test and treat in HIV: success could depend on rapid detection. Lancet 2011; 378:204-206.
79. Jones L, Akugizibwe P, Clayton M, et al. Costing human rights and community support interventions as a part of universal access to HIV treatment and care in a Southern African setting. Curr HIV Res 2011; 9:416-428.
80. Auvert B, Buve A, Ferry B, et al. Ecological and individual level analysis of risk factors for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV infection. AIDS 2001; 15 (Suppl 4): S15-S30. (Pubitemid 32913001)
81. Auvert B, Buve A, Lagarde E, et al. Male circumcision and HIV infection in four cities in sub-Saharan Africa. AIDS 2001; 15 (Suppl 4):S31-S40. (Pubitemid 32913002)
82. Auvert B, Marseille E, Korenromp EL, et al. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. PLoS ONE 2008; 3:e2679. doi:10.1371/journal.pone. 0002679.
83. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298. doi:10.1371/journal.pmed.0020298. (Pubitemid 41735779)
84. Quinn TC. Circumcision and HIV transmission. Curr Opin Infect Dis 2007; 20:33-38. (Pubitemid 46052124)
85. Mills E, Cooper C, Anema A, Guyatt G. Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11 050 men. HIV Med 2008; 9:332-335. (Pubitemid 352015640)
86. Progress in male circumcision scale-up: country implementation and research update. WHO/UNAIDS, Geneva. 2010.